CO6761350A2 - Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis - Google Patents

Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis

Info

Publication number
CO6761350A2
CO6761350A2 CO13117697A CO13117697A CO6761350A2 CO 6761350 A2 CO6761350 A2 CO 6761350A2 CO 13117697 A CO13117697 A CO 13117697A CO 13117697 A CO13117697 A CO 13117697A CO 6761350 A2 CO6761350 A2 CO 6761350A2
Authority
CO
Colombia
Prior art keywords
dihydroimidazo
angiogenesis
diseases associated
derivatives
useful
Prior art date
Application number
CO13117697A
Other languages
English (en)
Inventor
William Johnston Scoot
Ningshu Liu
Manfred Mowes
Andrea Hagebarth
Ursula Monning
Ulf Bomer
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44999756&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6761350(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CO6761350A2 publication Critical patent/CO6761350A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Abstract

Nuevos compuestos de 2,3-dihidroimidazo[1,2-c]quinazolina. Composiciones farmacéuticas que contienen dichos compuestos. Uso de dichos compuestos o de dichas composiciones en la inhibición de la fosfotidilinositol-3-quinasa (PI3K) y en el tratamiento de enfermedades asociadas a la fosfotidilinositol-3-quinasa (PI3K), particularmente en el tratamiento de trastornos hiperproliferativos y/o relacionados con la angiogénesis, solos o en combinación con otros ingredientes activos.
CO13117697A 2010-11-11 2013-05-10 Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis CO6761350A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41255610P 2010-11-11 2010-11-11

Publications (1)

Publication Number Publication Date
CO6761350A2 true CO6761350A2 (es) 2013-09-30

Family

ID=44999756

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13117697A CO6761350A2 (es) 2010-11-11 2013-05-10 Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis

Country Status (31)

Country Link
US (2) US8895549B2 (es)
EP (1) EP2638045B1 (es)
JP (1) JP6196156B2 (es)
KR (1) KR20140003436A (es)
CN (1) CN102906094B (es)
AP (1) AP3337A (es)
AR (1) AR083842A1 (es)
AU (1) AU2011328192B2 (es)
BR (1) BR112013011634A2 (es)
CA (1) CA2817317C (es)
CL (1) CL2013001295A1 (es)
CO (1) CO6761350A2 (es)
CR (1) CR20130213A (es)
CU (1) CU20130069A7 (es)
DO (1) DOP2013000105A (es)
EA (1) EA024406B1 (es)
EC (1) ECSP13012618A (es)
GT (1) GT201300121A (es)
HK (1) HK1180685A1 (es)
IL (1) IL226066A0 (es)
MA (1) MA34655B1 (es)
MX (1) MX2013005305A (es)
MY (1) MY164730A (es)
NZ (1) NZ610018A (es)
PE (1) PE20140411A1 (es)
SG (1) SG190100A1 (es)
TW (1) TW201305170A (es)
UA (1) UA113280C2 (es)
UY (1) UY33719A (es)
WO (1) WO2012062748A1 (es)
ZA (1) ZA201304244B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA113280C2 (xx) * 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
CA2817312A1 (en) * 2010-11-11 2012-05-18 Bayer Intellectual Property Gmbh Alkoxy-substituted 2,3-dihydroimidazo[1,2-c]quinazolines
CA2817287A1 (en) * 2010-11-11 2012-05-18 Bayer Intellectual Property Gmbh Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
CN103214489B (zh) * 2013-02-25 2016-10-26 中国人民解放军第二军医大学 一类具有抗肿瘤活性的多靶点激酶抑制剂及其制备方法
UA119537C2 (uk) * 2013-04-08 2019-07-10 Байєр Фарма Акцієнгезелльшафт ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ
WO2015082376A2 (en) 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Use of pi3k-inhibitors
EP3077003A1 (en) 2013-12-03 2016-10-12 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
CN105934256B (zh) 2013-12-03 2019-12-27 拜耳制药股份公司 Pi3k-抑制剂的组合产品
WO2016071380A1 (en) * 2014-11-07 2016-05-12 Bayer Pharma Aktiengesellschaft Synthesis of pi3k inhibitor and salts thereof
WO2016071382A1 (en) * 2014-11-07 2016-05-12 Bayer Pharma Aktiengesellschaft Synthesis of pi3k inhibitor and salts thereof
WO2016087490A1 (en) * 2014-12-03 2016-06-09 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
WO2016087488A1 (en) * 2014-12-03 2016-06-09 Bayer Pharma Aktiengesellschaft Administration regime for aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives
KR20180104597A (ko) 2015-11-07 2018-09-21 멀티비르 인코포레이티드 암 치료를 위한 종양 억제 유전자 요법 및 면역관문 봉쇄를 포함하는 조성물
CA3037626A1 (en) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
US20200009203A1 (en) 2016-12-12 2020-01-09 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors
WO2019002068A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag COMBINATION OF A PI3K INHIBITOR AND AN ANDROGEN RECEPTOR ANTAGONIST
KR20200135986A (ko) 2018-03-19 2020-12-04 멀티비르 인코포레이티드 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물
CN108383849B (zh) * 2018-04-26 2020-11-06 浙江大学 咪唑并喹唑啉衍生物及其在抗肿瘤抗炎中的应用
SG11202108752YA (en) * 2019-03-07 2021-09-29 BioNTech SE Process for the preparation of a substituted imidazoquinoline
WO2021074227A1 (en) * 2019-10-15 2021-04-22 Bayer Aktiengesellschaft 2-methyl-aza-quinazolines
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
WO2021260443A1 (en) 2020-06-24 2021-12-30 Bayer Aktiengesellschaft Combinations of 2,3-dihydroimidazo[1,2-c]quinazolines
CN113512040B (zh) * 2021-08-25 2023-10-13 河南牧业经济学院 一种血根碱仿生化合物及其制备方法
WO2023205680A1 (en) * 2022-04-20 2023-10-26 Synnovation Therapeutics, Inc. PI3Kα INHIBITORS
WO2023230262A1 (en) * 2022-05-26 2023-11-30 Synnovation Therapeutics, Inc. Tricyclic compounds as pi3kalpha inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
GB9400680D0 (en) 1994-01-14 1994-03-09 Sandoz Ltd Improvements in or relating to organic compounds
US5792766A (en) 1996-03-13 1998-08-11 Neurogen Corporation Imidazo 1,5-c! quinazolines; a new class of GABA brain receptor ligands
AU2003293310B2 (en) * 2002-09-30 2010-04-01 Bayer Intellectual Property Gmbh Fused azole-pyrimidine derivatives
PL1667992T3 (pl) 2003-09-19 2007-05-31 Astrazeneca Ab Pochodne chinazoliny
MXPA06003705A (es) * 2003-10-03 2006-06-20 3M Innovative Properties Co Imidazoquinolinas sustituidas con alcoxi.
EP1719771A1 (en) * 2004-02-19 2006-11-08 Takeda Pharmaceutical Company Limited Pyrazoloquinolone derivative and use thereof
US7994181B2 (en) 2006-08-03 2011-08-09 Rottapharm S.P.A. 6-1H-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agents
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
GB2454549B (en) * 2007-09-25 2009-09-23 Medical & Pharm Ind Tech & Dev Uses of 2-[piperidinyl]methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one for providing an anti-allergic effect and histamine H1 receptor antagonism effect
JP2011524383A (ja) 2008-06-20 2011-09-01 ロッタファルム・ソシエタ・ペル・アチオニ ６−１ｈ−イミダゾ−キナゾリンおよびキノリン誘導体、新規ｍａｏ阻害剤およびイミダゾリンレセプターリガンド
CN102076689B (zh) 2008-06-26 2014-10-15 内尔维阿诺医学科学有限公司 吡唑并-喹唑啉类
EP2168583A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
SG184550A1 (en) 2010-04-16 2012-11-29 Bayer Ip Gmbh Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
CA2817287A1 (en) * 2010-11-11 2012-05-18 Bayer Intellectual Property Gmbh Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines
CA2817312A1 (en) * 2010-11-11 2012-05-18 Bayer Intellectual Property Gmbh Alkoxy-substituted 2,3-dihydroimidazo[1,2-c]quinazolines
UA113280C2 (xx) * 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ

Also Published As

Publication number Publication date
DOP2013000105A (es) 2013-09-30
AU2011328192B2 (en) 2016-09-01
EA201300556A1 (ru) 2013-10-30
MY164730A (en) 2018-01-30
US8895549B2 (en) 2014-11-25
JP6196156B2 (ja) 2017-09-13
AP3337A (en) 2015-07-31
US20150080374A1 (en) 2015-03-19
HK1180685A1 (zh) 2013-10-25
PE20140411A1 (es) 2014-04-13
IL226066A0 (en) 2013-06-27
EP2638045B1 (en) 2022-08-31
AU2011328192A1 (en) 2013-05-02
NZ610018A (en) 2016-03-31
ECSP13012618A (es) 2013-07-31
US9902727B2 (en) 2018-02-27
CA2817317C (en) 2020-07-14
US20130317004A1 (en) 2013-11-28
CN102906094B (zh) 2016-06-22
KR20140003436A (ko) 2014-01-09
ZA201304244B (en) 2014-12-23
AR083842A1 (es) 2013-03-27
MX2013005305A (es) 2013-06-13
SG190100A1 (en) 2013-07-31
JP2013542238A (ja) 2013-11-21
GT201300121A (es) 2014-12-22
EA024406B1 (ru) 2016-09-30
UA113280C2 (xx) 2017-01-10
AP2013006921A0 (en) 2013-06-30
WO2012062748A1 (en) 2012-05-18
MA34655B1 (fr) 2013-11-02
TW201305170A (zh) 2013-02-01
UY33719A (es) 2012-06-29
CL2013001295A1 (es) 2013-10-04
CR20130213A (es) 2013-07-01
CN102906094A (zh) 2013-01-30
CU20130069A7 (es) 2013-09-27
BR112013011634A2 (pt) 2018-12-11
EP2638045A1 (en) 2013-09-18
CA2817317A1 (en) 2012-05-18

Similar Documents

Publication Publication Date Title
CO6761350A2 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
ECSP099387A (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogénesis
CL2011003346A1 (es) Compuestos derivados de 2,3-dihidro-5h-[1,3]tiazolo[3,2-a]pirimidin-5-ona, moduladores de pi3k; composicion farmaceutica; y uso para tratar una enfermedad de base inmunologica, cancer o enfermedad pulmonar en un paciente.
UY37149A (es) 2–amino–n–[7–metoxi–2,3–dihidroimidazo–[1,2–c]quinazolin–5–il]pirimidin–5–carboxamidas
UY33616A (es) Compuestos con estructura de imidazotriazinona
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
ECSP077324A (es) Amidas bicíclicas como inhibidores de cinasa
DK2321321T3 (da) Triazolo [4,5-d]pyramidinderivater og anvendelse deraf som purinreceptorantagonister
BRPI0717845A2 (pt) Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
CL2012002497A1 (es) Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras.
CL2007003523A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
EA200802118A1 (ru) Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
CL2013002177A1 (es) Compuestos derivados de 9h-purinas y 7h-pirrolo[2,3-d]-pirimidinas sustituidas, inhibidores de la pi3k de clase i y/o mtor; su composicon farmaceutica; su combinacion farmaceutica; y su uso en el tratamiento o la prevencion del cancer o trastornos neurodegenerativos.
AR047928A1 (es) Derivados de tetrahidropiridoindol
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
CR20120605A (es) Formulación tópica para un inhibidor de jak
GT200900056A (es) Benzoxazoles y oxazolopiridinas utiles como inhibidores de la quinasa janus
CL2011000124A1 (es) Compuestos derivados de 3-aril-4-heterociclil-pirazoles, inhibidores de proteina quinasa b-raf; metodo de inhibicion in vitro de la proteina quinasa b-raf; composicion farmaceutica; producto de combinacion farmaceutica; y su uso para el tratamiento del cancer.
CL2008001721A1 (es) Compuestos derivados de 17-beta-ciano-18 alfa-homo-19-nor-androst-4-eno; que presentan actividad gestagena y antimineralcorticoide; composicion farmaceutica; y uso en el tratamiento de trastornos pre-peri-y posmenopausicos y trastornos premenstruales.
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
BR112016011065A8 (pt) composto cristalino, composição farmacêutica, forma de dosagem, método para tratar anemia
UY33503A (es) Imidazo [1,2-a]pirimidinas y piridinas sustituidas

Legal Events

Date Code Title Description
FC Application refused